Rates in Bronchiolitis Hospitalization, Intensive Care Unit Use, Mortality, and Costs From 2004 to 2018

Abstract

IMPORTANCE Over the last 2 decades, bronchiolitis guidelines and improvement efforts focused on supportive care and reducing unnecessary tests, treatments, and hospitalization. There have been limited population-based studies examining hospitalization outcomes over time. OBJECTIVE To describe rates and trends in bronchiolitis hospitalization, intensive care unit (ICU) use, mortality, and costs. DESIGN, SETTING, AND PARTICIPANTS This cohort study used population-based health administrative data from April 1, 2004, to March 31, 2018, to identify bronchiolitis encounters using hospital discharge diagnosis codes in Ontario, Canada. Children younger than 2 years with and without bronchiolitis hospitalization were included. Data were analyzed from January 2020 to July 2021. MAIN OUTCOMES AND MEASURES Bronchiolitis hospitalization per 1000 person-years, ICU use per 1000 hospitalizations, mortality per 100 000 person-years, and costs per 1000 person-years adjusted to 2018 Canadian dollars and reported in 2018 US dollars.RESULTS Among 2 336 446 included children, 1 199 173 (51.3%) were male. During the study period, 43 993 children (1.9%) younger than 2 years had 48 058 bronchiolitis hospitalizations at 141 hospitals. Bronchiolitis accounted for 48 058 of 360 920 all-cause hospitalizations (13.3%) and 215 654 of 2 566 348 all-cause hospital days (8.4%) in children younger than 2 years. Bronchiolitis hospitalization was stable over time, at 14.0 (95% CI, 13.6-14.4) hospitalizations per 1000 person-years in 2004-2005 and 12.7 (95% CI, 12.2-13.1) hospitalizations per 1000 person-years in 2017-2018 (annual percent change [APC], 0%;

Preventing Respiratory Syncytial Virus in Children in France: A Narrative Review of the Importance of a Reinforced Partnership Between Parents, Healthcare Professionals, and Public Health Authorities

“…The mean estimated cost per hospitalisation in children younger than 1 year old was €2607. As observed in others counties, ICU use and cost has increased substantially in recent years in France [ 42 ]. Data from the University Hospital of Lyon show that the cost of hospitalisation per child over four successive RSV seasons (2014–2016) was higher in children younger than 1 month (€4892 for a 5.0-day median stay) than in those aged 1–3 months (€3958 for a 4.0-day median stay) and in those aged 3 months to 1 year (€3234 for a 4.0-day median stay) [ 43 ].…”

Increased use of high-flow nasal cannulas after the pandemic in bronchiolitis: a more severe disease or a changed physician’s attitude?

“…Furthermore, we found that the increase in HFNC, NIV/CPAP use, and NICU/PICU admission could be traced to a worldwide trend in augmenting the intensity of bronchiolitis care over the past 14 years. However, the stagnation in the hospitalization rate and population characteristics [15] suggests a more aggressive attitude of clinicians rather than a more severe disease [14]. According to the first studies, HFNC initially appeared to prevent intubation, especially if started early [16,17].…”

Improving Pediatric Intensive Care Unit Discharge Timeliness of Infants with Bronchiolitis Using Clinical Decision Support

“…Viral bronchiolitis can cause acute respiratory failure and is one of the most common causes for admission to a PICU [5][6][7] . Such critically ill children are often supported with non-invasive positive pressure ventilation (NIPPV) or high-flow nasal cannula (HFNC) respiratory support modalities.…”